Thermo Fisher Scientific Inc.

Who owns Thermo Fisher Scientific?
Thermo Fisher Scientific is an independent publicly traded company listed on the NYSE under TMO. No single shareholder controls it; ownership is spread across institutional investors and the public.

When was Thermo Fisher formed?
Thermo Fisher Scientific was created in 2006 by the merger of Thermo Electron, founded in 1956, and Fisher Scientific, founded in 1902.

What brands does Thermo Fisher own?
Its major brands are Thermo Scientific, Fisher Scientific, Applied Biosystems, Invitrogen, Unity Lab Services, Patheon, and PPD.

Who is the CEO of Thermo Fisher?
Marc Casper has been chairman, president, and CEO since 2009. He joined Thermo Electron in 2001 and led the company through the 2006 merger.

What was Thermo Fisher's revenue in 2025?
Revenue was $44.56 billion in fiscal 2025, up 4% from $42.88 billion in 2024. GAAP diluted EPS was $17.74.

What does PPD do?
PPD is Thermo Fisher's contract research organization, acquired in 2021 for $17.4 billion. It manages clinical trials and development programs for pharmaceutical and biotech clients.

The company combines two lineages. Thermo Electron was founded in 1956 in Belmont, Massachusetts, by George Hatsopoulos and Peter Nomikos to commercialize thermal energy technology. It grew through decades of acquisitions into analytical instruments and environmental monitoring.

Fisher Scientific was founded in 1902 in Pittsburgh by Chester G. Fisher as a supplier of laboratory equipment and chemicals. It moved into catalog distribution, becoming the dominant channel through which laboratories buy supplies.

In May 2006, Thermo Electron and Fisher Scientific announced a $10.6 billion merger of equals, creating Thermo Fisher Scientific. Marc Casper, a Thermo Electron veteran who joined the company in 2001, became CEO in 2009 and has led it since.

The merged company then built a life sciences and services empire through large acquisitions. In 2013 it announced the $13.6 billion purchase of Life Technologies, the Carlsbad, California, company formed by the 2008 merger of Invitrogen and Applied Biosystems. In 2017 it bought Patheon, a contract development and manufacturing organization, for $7.2 billion. In 2021 it completed the $17.4 billion acquisition of PPD, a contract research organization, adding clinical trial services.

During the COVID-19 pandemic, Thermo Fisher revenue surged on demand for PCR tests, instruments, and vaccine manufacturing support, peaking at $44.9 billion in 2022. Revenue declined in 2023 and 2024 as pandemic-related sales fell off, then returned to growth in 2025 at $44.56 billion.

In 2025, Thermo Fisher committed about $13 billion to acquisitions, including the $4.1 billion purchase of Solventum's purification and filtration business, which expanded its bioprocessing portfolio. The company continued to invest in U.S. manufacturing capacity and in 2026 announced further bioproduction expansions.

Thermo Fisher publishes an annual corporate social responsibility report and has committed to net-zero emissions by 2050, with interim targets validated by the Science Based Targets initiative. Programs include greener product design under its Greener by Design initiative and waste reduction across manufacturing sites. The company reports through CDP and major ESG frameworks.

Thermo Fisher appears on the Fortune 500 and Fortune's World's Most Admired Companies lists and has been recognized by organizations such as CPhi for pharmaceutical services. It ranks among the largest R&D and manufacturing employers in Massachusetts.

Thermo Fisher has faced criticism for selling DNA analysis equipment used by authorities in Xinjiang, China, where human rights groups allege the technology supported mass surveillance of Uyghurs. The company said in 2021 it would stop sales of such equipment in Xinjiang. Like other large diagnostic and pharma service companies, it also operates under extensive FDA, CMS, and international regulation and periodically faces product recalls and warning letters that it discloses in regulatory filings.